PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10746169-1	1999	The reversal effect of itraconazole on P-glycoprotein (P-gp)-mediated resistance of vinblastine, daunorubicin and doxorubicin was analyzed from a cellular pharmacokinetic point of view, namely by [3H]azidopine photoaffinity labeling, intracellular accumulation and transcellular transport experiments.	Itraconazole	23-35	phosphoglycolate phosphatase	Homo sapiens	55-59	
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Itraconazole	55-67	phosphoglycolate phosphatase	Homo sapiens	145-149	
10746169-4	1999	[3H]Azidopine photoaffinity labeling demonstrated that itraconazole, vinblastine, daunorubicin and doxorubicin showed higher binding ability for P-gp compared with digoxin, suggesting the following results were via P-gp.	Itraconazole	55-67	phosphoglycolate phosphatase	Homo sapiens	215-219	
10746169-7	1999	However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P-gp mediated transport from the intracellular space to apical side.	Itraconazole	118-130	phosphoglycolate phosphatase	Homo sapiens	141-145	
10746169-7	1999	However, their basal-to-apical transport was hardly affected by itraconazole, and this was explained by the fact that itraconazole inhibited P-gp, and subsequently increased their intracellular concentration and then the non-P-gp mediated transport from the intracellular space to apical side.	Itraconazole	118-130	phosphoglycolate phosphatase	Homo sapiens	225-229	
10746169-8	1999	The apical-to-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.	Itraconazole	105-117	phosphoglycolate phosphatase	Homo sapiens	174-178	
10746169-8	1999	The apical-to-basal transport of [3H]vinblastine, [3H]daunorubicin and [14C]doxorubicin was increased by itraconazole, and this was reasonably explained by the inhibition of P-gp, and partly also by the increase of their intracellular concentration via the inhibition of P-gp.	Itraconazole	105-117	phosphoglycolate phosphatase	Homo sapiens	271-275	
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	58-70	phosphoglycolate phosphatase	Homo sapiens	134-138	
34620694-6	2022	Three sensitive substrates were identified: avapritinib (CYP3A), lonafarnib (CYP3A), and relugolix (P-gp), with AUCRs of 7.00, 5.07, and 6.25 when co-administered with itraconazole, ketoconazole, and erythromycin, respectively.	Itraconazole	168-180	phosphoglycolate phosphatase	Homo sapiens	100-104	
33964991-4	2021	We thus conducted this study to investigate the effect of itraconazole (ICZ), a strong inhibitor of CYP3A and a moderate inhibitor of P-gp, on the pharmacokinetics (PK) of FDV.	Itraconazole	72-75	phosphoglycolate phosphatase	Homo sapiens	134-138	
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	phosphoglycolate phosphatase	Homo sapiens	125-145	
30845347-1	2019	AIMS: This phase I study evaluated the effects of the moderate cytochrome P450 (CYP) 3A inhibitor fluconazole and the strong CYP3A/P-glycoprotein (P-gp) inhibitor itraconazole on the pharmacokinetics of the investigational neural precursor cell expressed, developmentally downregulated 8 (NEDD8)-activating enzyme inhibitor pevonedistat in patients with advanced solid tumours.	Itraconazole	163-175	phosphoglycolate phosphatase	Homo sapiens	147-151	
30091221-0	2018	PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.	Itraconazole	82-94	phosphoglycolate phosphatase	Homo sapiens	27-31	
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	0-12	phosphoglycolate phosphatase	Homo sapiens	57-61	
19356088-2	2008	Itraconazole (ITZ) functions as an inhibitor of both the P-gp and CYP3A and is used as a fungistatic/fungicidal agent in human and veterinary medicine.	Itraconazole	14-17	phosphoglycolate phosphatase	Homo sapiens	57-61